ischaemic stroke | pharmaphorum

Skip to main content

Monday 12 January 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

ischaemic stroke

News

An older man holds his head in pain while lights flash

Stroke data breathes life back into Bayer's asundexian

Prospects for Bayer's oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.

News

Roche ends the 30-year US hiatus in new stroke drugs

Roche ends the 30-year US hiatus in new stroke drugs

Genentech has won FDA approval for its clot-buster TNKase as a treatment for acute ischaemic stroke, after almost abandoning the project in 2023.

R&D

Hands holding brain with puzzle

Sponsored

Innovative sublingual medication for improved stroke care

Stroke poses a major threat to public health, and this threat is predicted to worsen in the years to come.

Digital

lightbulb with light molecules inside

Sponsored

Embracing innovation to drive clinical change in UK stroke c...

Medical technology (MedTech) companies go through a vigorous process to introduce their solutions into a clinical environment.

Editor's Picks

Servier signs €1bn-plus AI pact with Iktos

Hengrui gets first OK for a PD-L1/TGF-beta drug for cancer

Rumour confirmed as Lilly buys Ventyx for $1.2 billion

Court blocks HHS' 340B rebate programme pilot

Bayer's Monsanto sues mRNA COVID-19 vaccine makers

News

JPM: AbbVie pays $650m upfront for RemeGen cancer drug

JPM: AbbVie pays $650m upfront for RemeGen cancer drug

AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company